Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ghaddar, Habib
PRESERVE-003, NCT05671510: ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors	Active, not recruiting	3	600	Europe, Canada, US, RoW	Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere	OncoC4, Inc., BioNTech SE	Non Small Cell Lung Cancer	06/26	06/27
NCT06322693: A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)	Recruiting	1	475	Europe, US, RoW	TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin	GlaxoSmithKline	Neoplasms	08/25	02/27
AMBER, NCT02817633: A Study of TSR-022 in Participants With Advanced Solid Tumors Oct 2019 - Mar 2020 : From AMBER trial From AMBER trial at SITC 2018 [screenshot] Nov 2018 - Nov 2018: From AMBER trial at SITC 2018 [screenshot] From AMBER trial in combination with TSR-022 at SITC 2018 Nov 2018 - Nov 2018: From AMBER trial in combination with TSR-022 at SITC 2018	Recruiting	1	447	Europe, US, RoW	TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin	Tesaro, Inc.	Neoplasms	04/25	04/27